相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiorespiratory fitness in patients with type 2 diabetes: A missing piece of the puzzle
Marijana Tadic et al.
HEART FAILURE REVIEWS (2021)
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning
Daniel J. Drucker
CELL METABOLISM (2021)
Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care
Marco Orsini Federici et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2021)
Hypoxia and hypoxia-inducible factors in diabetes and its complications
Sergiu-Bogdan Catrina et al.
DIABETOLOGIA (2021)
COVID-19 and metabolic diseases: a heightened awareness of health inequities and a renewed focus for research priorities
William T. Cefalu et al.
CELL METABOLISM (2021)
Metabolically Healthy Obesity and the Risk of Cardiovascular Disease in the General Population - Analysis of a Nationwide Epidemiological Database
Hidetaka Itoh et al.
CIRCULATION JOURNAL (2021)
The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial
Clare A. Whicher et al.
DIABETES OBESITY & METABOLISM (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cardiovascular Imaging in Obesity
Sophie Mavrogeni et al.
NUTRIENTS (2021)
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
M. S. Capehorn et al.
DIABETES & METABOLISM (2020)
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Laerke S. Gasbjerg et al.
PEPTIDES (2020)
Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring
Olga Panagiotopoulou et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2020)
Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome
Michael J. Wilkinson et al.
CELL METABOLISM (2020)
Alzheimer's Disease and Diabetes: Insulin Signaling as the Bridge Linking Two Pathologies
Jonathan Chang-Cheng Shieh et al.
MOLECULAR NEUROBIOLOGY (2020)
Brain-Sparing Sympathofacilitators Mitigate Obesity without Adverse Cardiovascular Effects
Ines Mahu et al.
CELL METABOLISM (2020)
Mechanisms behind Retinal Ganglion Cell Loss in Diabetes and Therapeutic Approach
Maria Constanza Potilinski et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
Daisuke Yabe et al.
Lancet Diabetes & Endocrinology (2020)
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Yuichiro Yamada et al.
Lancet Diabetes & Endocrinology (2020)
Severe Obesity as an Independent Risk Factor for COVID-19 Mortality in Hospitalized Patients Younger than 50
Eyal Klang et al.
OBESITY (2020)
The risk of cardiovascular complications with current obesity drugs
Ariana M. Chao et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Effects of 4-and 6-h Time-Restricted Feeding on Weight and Cardiometabolic Health: A Randomized Controlled Trial in Adults with Obesity
Sofia Cienfuegos et al.
CELL METABOLISM (2020)
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea The PIONEER 3 Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Bernard Zinman et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Vanita R. Aroda et al.
DIABETES CARE (2019)
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study
Richard E. Pratley et al.
DIABETES OBESITY & METABOLISM (2019)
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard Pratley et al.
LANCET (2019)
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
Thomas R. Pieber et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice
Youngmi Song et al.
CELL METABOLISM (2019)
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
Bernard Zinman et al.
DIABETES CARE (2019)
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard et al.
DIABETES CARE (2019)
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
Ildiko Lingvay et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Adipocyte Hypoxia-Inducible Factor 2α Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism
Xingzhong Zhang et al.
CELL METABOLISM (2019)
The link between diabetes and atherosclerosis
Lucia La Sala et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2019)
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
Stephen C. Bain et al.
DIABETES OBESITY & METABOLISM (2019)
A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials
Vanita R. Aroda
DIABETES OBESITY & METABOLISM (2018)
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
Helena W. Rodbard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity
Julie B. Hjerpsted et al.
DIABETES OBESITY & METABOLISM (2018)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew J. Ahmann et al.
DIABETES CARE (2018)
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
Per Lundkvist et al.
DIABETES OBESITY & METABOLISM (2017)
Mechanisms, Pathophysiology, and Management of Obesity
Steven B. Heymsfield et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Bo Ahren et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Christopher Sorli et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Vanita R. Aroda et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
W. Timothy Garvey et al.
ENDOCRINE PRACTICE (2016)
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Luc Van Gaal et al.
DIABETES CARE (2015)
European Guidelines for Obesity Management in Adults
Volkan Yumuk et al.
OBESITY FACTS (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010
Sarah Stark Casagrande et al.
DIABETES CARE (2013)
GLP-1 receptor activated insulin secretion from pancreatic ss-cells: mechanism and glucose dependence
A. R. Meloni et al.
DIABETES OBESITY & METABOLISM (2013)
Anti-obesity drugs: past, present and future
R. John Rodgers et al.
DISEASE MODELS & MECHANISMS (2012)
The FDA's Assessment of Two Drugs for Chronic Weight Management
Eric Colman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Is There a Place for Dietary Fiber Supplements in Weight Management?
Michael R. Lyon et al.
CURRENT OBESITY REPORTS (2012)
Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
Julio Rosenstock et al.
DIABETES CARE (2010)
GLUT2 mutations, translocation, and receptor function in diet sugar managing
Armelle Leturque et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup et al.
LANCET (2009)
Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese patients Pooled 1-year data from the Rimonabant in Obesity (RIO) program
Luc Van Gaal et al.
DIABETES CARE (2008)
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Maire E. Doyle et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Glucagon-like peptide-1: Regulation of insulin secretion and therapeutic potential
J Gromada et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2004)
Voltage-dependent K+ channels in pancreatic beta cells:: Role, regulation and potential as therapeutic targets
PE MacDonald et al.
DIABETOLOGIA (2003)
分享论文
